title: Antidepressant-like action of nicotine in forced swimming test and brain serotonin in mice.
abstract: An antidepressant-like action of nicotine has been suggested in the forced swimming test. The aim of the present study was to evaluate the relationship between the antidepressant-like action of nicotine and brain serotonin (5-HT) in mice. Nicotine at a dose of 0.2 mg/kg significantly (p < 0.05) decreased the duration of immobility time in forced swimming test. However, nicotine (0.01-1 mg/kg, s.c.) had no effect on locomotor activity in open-field test. Dopamine turnover in mouse whole brain was increased by nicotine (0.01-1 mg/kg, s.c.) in a dose-dependent manner, and nicotine at a dose of 0.05 mg/kg showed a significant increases in 5-HT turnover. Nicotine at a dose of 0.05 mg/kg markedly enhanced head twitch responses induced by (+/-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI), a selective 5-HT2A/2C receptor agonist. These findings suggest that the involvement of nicotinic and serotonergic systems in the antidepressant-like effects of nicotine.
authors.affiliation: Division of Pharmacy, Ehime University Hospital, Shitsukawa Toon, Ehime, 791-0295, Japan. suemaru@m.ehime-u.ac.jp
authors.forename: Katsuya
authors.initials: K
authors.lastname: Suemaru
authors.forename: Kayo
authors.initials: K
authors.lastname: Yasuda
authors.forename: Ranji
authors.initials: R
authors.lastname: Cui
authors.forename: Bingjin
authors.initials: B
authors.lastname: Li
authors.forename: Kenta
authors.initials: K
authors.lastname: Umeda
authors.forename: Manabu
authors.initials: M
authors.lastname: Amano
authors.forename: Hiromi
authors.initials: H
authors.lastname: Mitsuhashi
authors.forename: Nobuhito
authors.initials: N
authors.lastname: Takeuchi
authors.forename: Tomoyoshi
authors.initials: T
authors.lastname: Inoue
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Gomita
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Araki
mesh_terms: D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D000662:Amphetamines / Q000494:pharmacology; D000818:Animals; D000928:Antidepressive Agents; D001923:Brain Chemistry / Q000187:drug effects*; D004298:Dopamine / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D019416:Head Movements / Q000187:drug effects; D007279:Injections, Subcutaneous; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009043:Motor Activity / Q000187:drug effects; D009538:Nicotine / Q000494:pharmacology*; D018722:Nicotinic Agonists / Q000494:pharmacology*; D044402:Receptor, Serotonin, 5-HT2A / Q000187:drug effects; D044405:Receptor, Serotonin, 5-HT2C / Q000187:drug effects; D012701:Serotonin / Q000378:metabolism*; D018490:Serotonin Agents / Q000494:pharmacology; D017366:Serotonin Receptor Agonists / Q000494:pharmacology; D013550:Swimming / Q000523:psychology*
chemical_list: D000662:Amphetamines; D000928:Antidepressive Agents; D018722:Nicotinic Agonists; D044402:Receptor, Serotonin, 5-HT2A; D044405:Receptor, Serotonin, 5-HT2C; D018490:Serotonin Agents; D017366:Serotonin Receptor Agonists; D015102:3,4-Dihydroxyphenylacetic Acid; D012701:Serotonin; D009538:Nicotine; C015952:4-iodo-2,5-dimethoxyphenylisopropylamine; D004298:Dopamine